Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Annual Patient and Caregiver Burden of Oncology Clinic Visits for Granulocyte-Colony Stimulating Factor (G-CSF) Therapy in the United States (US)

Mark Stephens, Xiaoyan Li, PhD, Maureen Reiner, Wayne Sheldon, Spiros Tzivelekis, MSc

Blood (2015) 126 (23): 2066.

https://doi.org/10.1182/blood.V126.23.2066.2066

Published: 2015

Journal Articles

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Derek Weycker, PhD, Xiaoyan Li, PhD, Rich Barron, M.S., Hongsheng Wu, PhD, Phuong Khanh Morrow, MD, Hairong Xu, MD, PhD, Maureen Reiner, M.S., Jacob Garcia, MD, Shivani Mhatre, M.S., Gary H. Lyman, MD MPH

Blood (2014) 124 (21): 4824.

https://doi.org/10.1182/blood.V124.21.4824.4824

Published: 2014

Journal Articles

Relationship Between Severity and Duration of Chemotherapy Induced Neutropenia and Risk of Infection Among Patients with Non-Myeloid Malignancies

Yanli Li, MDPhD, Xiaolong Shih, PhD, Zandra K. Klippel, MD, Maureen Reiner, M.S., John H Page, MD ScD

Blood (2014) 124 (21): 4960.

https://doi.org/10.1182/blood.V124.21.4960.4960

Published: 2014

Journal Articles

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Michael Burns, BS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Michele Cottler-Fox, MD

Blood (2005) 106 (11): 1972.

https://doi.org/10.1182/blood.V106.11.1972.1972

Published: 2005

Journal Articles

Melphalan 200mg/m 2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 839.

https://doi.org/10.1182/blood.V106.11.839.839

Published: 2005

Journal Articles

Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years.

Frits van Rhee, Guido Tricot, Elias Anaissie, Maureen Reiner, Maurizio Zangari, Michael Burns, Joshua Epstein, John Shaughnessy, Erik Rasmussen, John Crowley

Blood (2005) 106 (11): 1149.

https://doi.org/10.1182/blood.V106.11.1149.1149

Published: 2005

Journal Articles

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Elias Anaissie, MD, Teresa Milner, BS, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 1157.

https://doi.org/10.1182/blood.V106.11.1157.1157

Published: 2005

Journal Articles

Low Frequency of Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM), Especially If AT Is Applied Early during Treatment.

Guido Tricot, Maureen Reiner, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Gordon Dewald, Michele Fox, Bart Barlogie

Blood (2005) 106 (11): 706.

https://doi.org/10.1182/blood.V106.11.706.706

Published: 2005

Journal Articles

A Complete Remission (CR) Is Not a Prerequisite for Prolonged Survival after Autotransplants for Multiple Myeloma.

Guido Tricot, MD, PhD, Maureen Reiner, PhD, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 926.

https://doi.org/10.1182/blood.V104.11.926.926

Published: 2004

Journal Articles

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Clyde Bailey, Maureen Reiner, Erik Rasmussen, Athanasios Fassas, MD, Maurizio Zangari, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 940.

https://doi.org/10.1182/blood.V104.11.940.940

Published: 2004

NARROW

Annual Patient and Caregiver Burden of Oncology Clinic Visits for Granulocyte-Colony Stimulating Factor (G-CSF) Therapy in the United States (US)

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Relationship Between Severity and Duration of Chemotherapy Induced Neutropenia and Risk of Infection Among Patients with Non-Myeloid Malignancies

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients.

Melphalan 200mg/m 2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.

Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years.

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Low Frequency of Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM), Especially If AT Is Applied Early during Treatment.

A Complete Remission (CR) Is Not a Prerequisite for Prolonged Survival after Autotransplants for Multiple Myeloma.

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only